Eli Lilly and Company (NYSE:LLY) Trading Down 0.7%

Eli Lilly and Company (NYSE:LLY)’s stock price traded down 0.7% during trading on Wednesday . The stock traded as low as $768.25 and last traded at $775.80. 824,797 shares traded hands during trading, a decline of 73% from the average session volume of 3,043,123 shares. The stock had previously closed at $781.10.

Analysts Set New Price Targets

Several equities research analysts have commented on the company. DZ Bank lowered Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price objective for the company. in a research note on Wednesday, February 21st. The Goldman Sachs Group upped their price objective on Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a report on Thursday, April 11th. Barclays upped their price objective on Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a report on Wednesday, February 7th. TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. Finally, Citigroup raised their price target on Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a research report on Tuesday, April 2nd. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $742.95.

Eli Lilly and Company Stock Performance

The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. The stock has a fifty day moving average of $761.41 and a 200-day moving average of $669.21. The stock has a market cap of $736.69 billion, a PE ratio of 133.47, a price-to-earnings-growth ratio of 1.61 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Tuesday, April 30th. The company reported $2.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The firm had revenue of $8.77 billion for the quarter, compared to analyst estimates of $8.94 billion. During the same quarter last year, the company posted $1.62 earnings per share. The business’s revenue was up 26.0% on a year-over-year basis. On average, equities analysts forecast that Eli Lilly and Company will post 12.51 EPS for the current year.

Institutional Investors Weigh In On Eli Lilly and Company

Institutional investors have recently added to or reduced their stakes in the business. Lipe & Dalton purchased a new stake in shares of Eli Lilly and Company during the 4th quarter worth approximately $26,000. Core Wealth Advisors Inc. boosted its stake in shares of Eli Lilly and Company by 188.2% during the 4th quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock worth $29,000 after acquiring an additional 32 shares in the last quarter. Thompson Investment Management Inc. purchased a new stake in shares of Eli Lilly and Company during the 3rd quarter worth approximately $27,000. Activest Wealth Management purchased a new stake in shares of Eli Lilly and Company during the 1st quarter worth approximately $39,000. Finally, Tidemark LLC purchased a new stake in shares of Eli Lilly and Company during the 4th quarter worth approximately $29,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.